Effect of Rifampin on the Pharmacokinetics of BAY73-4506
The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.
Neoplasms
DRUG: Regorafenib (BAY73-4506) + rifampin
Pharmacokinetic profile, after 1 month|Proportion of subjects with adverse event collection, after 35 days
The purpose of this study is to see if giving rifampin, a marketed antibiotic, changes how your body absorbs and distributes BAY73-4506.